Our Capital Markets team advised the syndicate composed of Jefferies, Leerink Partners, and Evercore ISI, acting as Joint Global Coordinators and Joint Bookrunners, as well as Oddo BHF SCA, acting as Joint Bookrunner, in connection with the €48 million private placement carried out by Medincell SA.
Both US and European healthcare investors, including Perceptive Advisors, Kurma Growth Opportunities Fund, Affinity Asset Advisors, and Polar Capital, participated in the transaction alongside Medincell’s historical shareholders.
The funds raised, combined with existing cash resources, are expected to support and accelerate the execution of Medincell’s growth strategy.
Goodwin had also advised the banks syndicate in connection with Medincell’s previous capital increase in 2025.
Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long‑acting injectable treatments across multiple therapeutic areas. Based near Montpellier, Medincell collaborates with leading pharmaceutical companies and foundations to advance global health through new treatment options.
The Goodwin team was composed of Guilhem Richard, Ben Marsh, Mariléna Gryparis, Jesse Fishman, and Shanna Kim.